Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342

Harris, Lyndsay N.; Broadwater, Gloria; Lin, Nancy U.; Miron, Alexander; Schnitt, Stuart J.; Cowan, David P.; Lara, Jonathan F.; Bleiweiss, Ira J.; Berry, Donald A.; Ellis, Matthew J.; Hayes, Daniel F.; Winer, Eric P.; Dressler, Lynn

doi:10.1186/bcr1622

Cited by 127 publications

(85 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Triple negative breast cancer is a heterogeneous disease with various genotypes within it. These group of patients are associated with grave prognosis and very less is been known about its behaviour from our subcontinent [14,15]. Basal like and triple negative terminology has been used vice versa without any clear cut demarcations.…”

Section: Discussionmentioning

confidence: 99%

Triple Negative Breast Cancer - Our Experience and Review

Krishnamurthy

Poornima

Challa

et al. 2012

Indian J Surg Oncol

View full text Add to dashboard Cite

Triple negative breast cancer (TNBC) constitutes 10-25% of patients with breast cancer. TNBC is an aggressive phenotype affecting younger age groups and has poor prognosis. We retrospectively analysed 50 triple negative breast cancer patients attending our outpatient department among 270 breast cancer patients. The incidence of TNBC was 18.5%, and most of them were premenopausal 56% (28/50) with mean age was 46.66±13.87 (Range 28-72 years). Most of them had Invasive ductal cancer 94% (47/50) and were high grade (Grade 3−96%)(48/50). Five patients presented with metastatic disease (2 patients only Skeletal, 1 patient with Skeletal and Lung, 1 patient with Lung and 1 patient with Liver) and 7 patients developed recurrence (all 7 had chest wall recurrence, 3 had supraclavicular lymph node recurrence, 2 had skeletal metastases and 1 had developed brain metastases) during follow up. The mean disease free survival was 15 months (Range 3-58 months) and overall survival was 20.14 months (Range 5-70 months). Fifty six percent (28/50) of patients were premenopausal and mean age of presentation was 46.66±13.87 years (Range 28-72 years). Ten percent (5/50) presented with metastatic disease and 15% (7/45) developed metastases during follow up. Five patients (10%) died during follow up. Hence, Triple negative breast cancer is aggressive, with rapid progression leading to mortality in younger patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Triple Negative Breast Cancer - Our Experience and Review

Krishnamurthy

Poornima

Challa

et al. 2012

Indian J Surg Oncol

View full text Add to dashboard Cite

show abstract

“…The NSABP B28 trial consisted of in 3,060 patients and compared treatments with doxorubicin and cyclophosphamide combined with or without 4 cycles of paclitaxel; no significant difference was found in the relative risk of recurrence and overall survival with regard to hormone receptor status (17). In the CALGB 9342 trial, which assessed three paclitaxel doses for metastatic breast cancer, no significant difference was observed in the time to treatment failure or response rate between triple-negative and hormone receptor-positive breast cancer; however, the overall survival time was found to be significantly lower in triple-negative breast cancer compared with hormone receptor-positive breast cancer (18).…”

Section: Discussionmentioning

confidence: 99%

Pathological complete response rate in hormone receptor-negative breast cancer treated with neoadjuvant FEC, followed by weekly paclitaxel administration: A retrospective study and review of the literature

Kiba¹,

Morii²,

Takahashi³

et al. 2016

Oncology Letters

View full text Add to dashboard Cite

Abstract. While tumor size, the presence of inflammatory carcinoma and lymph node involvement are the main prognostic factors of women with locally advanced breast cancer, the prognostic value of the estrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 (HER2) status has not been fully clarified. The present study examined the therapeutic efficacy of a neoadjuvant fluorouracil, epirubicin and cyclophosphamide regimen (FEC), followed by weekly paclitaxel and/or trastuzumab administration, in the treatment of hormone receptor-negative breast cancer patients. Between April 2012 and February 2014, 14 patients with hormone receptor-negative local breast cancer (triple-negative type, 9 patients; HER2 type, 5 patients) were included in the study. In all cases, the histological type of the primary cancer was invasive ductal carcinoma. Among the 14 women who received the regimen, 5 presented with stage I cancer (35.7%), 3 with stage IIA (21.4%), 3 with stage IIB (21.4%), 1 with stage IIIB (7.1%) and 2 with stage IIIC (14.3%), according to the American Joint Committee on Cancer staging system. With regard to the tumor-node-metastasis classification, 5 patients were T1N0M0 (35.7%), 3 were T2N0M0 (21.4%), 3 were T2N1M0 (21.4%), 2 were T3N3M0 (14.3%) and 1 was T4N1M0 (7.1%). The pathological response was evaluated using resected tissue following neoadjuvant chemotherapy, according to the criteria established by the Japanese Breast Cancer Society. Patients were classified into pathological responders (grades 2 and 3, 71.4% of all patients) and non-responders (grade 1, 28.6% of all patients). A pathological complete response (pCR) was achieved in 50.0% of all cases (7/14); 44.4% of triple-negative-type cases (4/9) and 60.0% of HER2-type cases (3/5). Hematological and non-hematological toxicity was reversible and manageable. No patients withdrew from treatment, and favorable compliance was achieved. The present study demonstrated that neoadjuvant FEC followed by weekly administration of paclitaxel and/or trastuzumab induces a high pathological response and a high pCR rate in patients with hormone receptor-negative breast cancer. Due to the high clinical benefit rate and acceptable safety profile, this regimen should be considered an acceptable neoadjuvant treatment option for hormone receptor-negative breast cancer. IntroductionNeoadjuvant therapy is a standard treatment option for breast cancer (1). It has been suggested that taxane-based chemotherapy is closely associated with improved outcomes in hormone receptor-negative or human epidermal growth factor receptor 2 (HER2)-positive disease, and little, if any, benefit from taxane-based chemotherapy has been observed for the ≥50% of patients with hormone receptor-positive and HER2-negative disease (2).Paclitaxel is considered a fundamental drug in the treatment of breast cancer (3). As a potent mitotic inhibitor, it used as an effective chemotherapeutic agent in the treatment of solid tumors. A randomized phase III trial reported that paclitaxel...

show abstract

“…The main characteristics of triple-negative cancers that have emerged from the literature illustrate their similarities to basal-like cancers, including the fact that they more frequently affect younger patients (o50 years), 24,30,31,59,61,62 are more prevalent in African-American women, [62][63][64] often present as interval cancers, and are significantly more aggressive than tumors of other molecular subtypes. 24,28,59,[61][62][63] This aggressiveness is best exemplified by the fact that the peak risk of recurrence is between the first and third years and the majority of deaths occur in the first 5 years following therapy.…”

Section: S Badve Et Almentioning

confidence: 99%

“…24,28,59,[61][62][63] This aggressiveness is best exemplified by the fact that the peak risk of recurrence is between the first and third years and the majority of deaths occur in the first 5 years following therapy. 59,61 Patients with triple-negative cancers, 59,63 similar to those with basal-like cancers, 42 have a significantly shorter survival following the first metastatic event when compared with those with non-basal-like/non-triple-negative controls.…”

Section: S Badve Et Almentioning

confidence: 99%

Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists

et al. 2011

Self Cite

View full text Add to dashboard Cite

Breast cancer is a heterogeneous disease encompassing a variety of entities with distinct morphological features and clinical behaviors. Although morphology is often associated with the pattern of molecular aberrations in breast cancers, it is also clear that tumors of the same histological type show remarkably different clinical behavior. This is particularly true for 'basal-like cancer', which is an entity defined using gene expression analysis. The purpose of this article was to review the current state of knowledge of basal-like breast cancers, to discuss the relationship between basal-like and triple-negative breast cancers, and to clarify practical implications of these diagnoses for pathologists and oncologists.

show abstract

Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342

Cited by 127 publications

References 45 publications

Triple Negative Breast Cancer - Our Experience and Review

Triple Negative Breast Cancer - Our Experience and Review

Pathological complete response rate in hormone receptor-negative breast cancer treated with neoadjuvant FEC, followed by weekly paclitaxel administration: A retrospective study and review of the literature

Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists

Contact Info

Product

Resources

About